Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

18 Apr 2019

New York, US and Vienna, Austria, April 17, 2019 - HOOKIPA Pharma Inc....

26 Feb 2019

The investment was led by Redmile Group with participation of additional new...

15 Feb 2019

Michael A. Kelly is a former senior executive of Amgen, Inc. currently acting...

2 Jan 2019

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave®...

17 Dec 2018

The Phase 2 clinical trial evaluates the safety and efficacy of HB-101

6 Dec 2018

Valneva is a biotech company developing and commercializing vaccines for...

all news

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

Our Mission

News

HOOKIPA Pharma Announces Pricing of Initial Public Offering

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

HOOKIPA Appoints Michael A. Kelly as Independent Director

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License...

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic...

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

Our Pipeline

Careers